Please login to the form below

Not currently logged in
Email:
Password:

Alkermes to buy Elan unit

Alkermes is to acquire Elan's drug formulation and manufacturing unit for $960m, with company headquarters to be moved to Ireland

US-based Alkermes is to acquire Elan Drug Technologies (EDT) – Elan's unit for drug formulation and manufacturing – for a total of around $960m, creating the newly formed Alkermes plc to be based in Ireland.

The deal has been approved by company boards, with Elan to receive $500m in cash and 31.9 million ordinary shares of Alkermes plc common stock.

Existing shareholders of Alkermes will receive one share of the new Alkermes plc in exchange for each current share owned.

The company said the deal will enable Alkermes to become a sustainably profitable biopharmaceutical company specialising in developing treatments in the field of central nervous system (CNS).

Richard Pops, current chairman, president and CEO of Alkermes, will serve as Alkermes plc's chairman and CEO. Current head of Elan Drug Technologies, Shane Cook, will become president of Alkermes plc.

Pops said: "This merger will bring the scale and resources for strategic and balanced investment across the whole product continuum, from R&D innovation to clinical development, to world-class manufacturing and commercial expansion. We're looking forward to working with the EDT team to accelerate growth and to create value for our shareholders and the patients we serve."

Cooke also commented on the deal, reference the company's future product prospects: "With EDT's two recently approved drugs, Invega Sustenna (paliperidone palmitate – for schizophrenia) and Ampyra (dalfampridine – for multiple scleroris), driving revenue growth, the EDT business is an ideal complement to Alkermes' portfolio of approved and development-stage drug."

Elan has a webcast of a conference call concerning the deal.

9th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

We are GCI Health, one of the world’s largest specialist health and medical communications agencies with global hubs in London...

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics